Navigation Links
Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
Date:9/10/2013

p>Boehringer Ingelheim has a comprehensive interferon-free clinical trial program, HCVerso®, which includes three pivotal Phase 3 studies. The HCVerso® studies aim to enroll approximately 1,100 treatment-naive and experienced HCV genotype-1b (GT-1b) patients, including those who are interferon eligible or ineligible, and those with compensated liver cirrhosis.

For more information regarding the trial, please visit www.clinicaltrials.gov.

About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso® and HCVerso®.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso®1 is the first of an ongoing multi-study Phase 3 trial program that is evaluating faldaprevir combined with PegIFN/RBV. Three additional trials in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV are near clinical completion. Deleobuvir, also known as BI 207127, is an investigational NS5B non-nucleoside polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations o
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
2. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
3. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
4. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
5. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
6. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
7. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
8. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
9. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
10. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
11. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Inc. (NASDAQ: CYBX ) today announced results for ... highlights 1   Operating results for the first ... fiscal 2014, and other achievements, include: , Worldwide net ... , Strong international net sales of $13.2 million, an increase ... net product sales reached a new high of $58.8 million, ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... HOLBROOK, N.Y. , Aug. 20, 2014 /PRNewswire/ ... MDIN) today announced that after months of hard ... finally finished the new Snorenz formulation and package ... vitamins E and B-6 back into the product ... well as longer lasting effects.  Snorenz Nighttime will ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2
... W.Va., June 19 Keeping your teeth brushed and flossed can ... and stroke, dentists have warned for years. Now researchers at ... help preserve memory. , , The National Institutes of Health ... further build on studies linking gum disease and mild to moderate ...
... Florida,s First Three-Year Neuroscience Research Doctorate Program , ... Roskamp Institute (Roskamp) today announced the first enrollment ... through which students will conduct full-time laboratory research ... is an Affiliated Research Centre (ARC) of the ...
Cached Medicine Technology:School of Dentistry Studies Link Between Oral Health and Memory 2Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program 2Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program 3
(Date:8/21/2014)... CA (PRWEB) August 21, 2014 Sleep Apnea ... across the U.S. This provides doctors with a convenient way ... find a doctor are that much closer to finding ... have no idea they are experiencing this sleep disorder ... receive treatment at all. , Thanks to Sleep Apnea Doctors ...
(Date:8/21/2014)... Cary, NC (PRWEB) August 21, 2014 ... solutions for the health and human services markets, announced ... features and capabilities incorporating the Tin Can API. ... and their employees have the most advanced mobile learning ... greatest in adult learning tools and techniques,” says Jim ...
(Date:8/21/2014)... ERT, a leading global solution ... endpoint data collection, today opened registration for ... Product Value with Optimized Endpoints. The ... developers to network with leading researchers as ... implementing, and justifying effective strategies for collecting ...
(Date:8/21/2014)... elicited by T-type calcium channels in the thalamic ... of calcium. These channels enable thalamic reticular nucleus ... to enter a hyper-excited state. , In order ... absence seizures, the researchers conducted an experiment to ... techniques to delete the T-type calcium channel CaV3.3. ...
(Date:8/21/2014)... Do we drive to work or take the train? From ... make hundreds of different decisions every day. Even if these ... for our long-term personal development to make decisions that are ... difficult, however. They are known to make impulsive decisions, often ... of making a choice that yields a greater reward later ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea Doctors US is Now Offering Complimentary Listings to Sleep Apnea Doctors Across the United States 2Health News:Relias Learning Announces Support for Tin Can API 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:ADHD children make poor decisions due to less differentiated learning processes 2
... SOUTH SAN FRANCISCO, Calif., July 29 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman ... overview, including a discussion about the clinical development program for ... conferences: , , , ...
... , SAN DIEGO, July 29, 2009 Arena ... will report second quarter 2009 financial results after the NASDAQ ... afternoon, Jack Lief, Arena,s President and Chief Executive Officer, and ... Officer, will host a conference call at 5:00 p.m. Eastern ...
... , JACKSONVILLE, Fla., July 29 Today, Wounded ... bill (H.R. 3155) that will assist the family caregivers of ... (S. 801) that would provide more comprehensive support and coverage ... need of these services. H.R. 3155, the Caregiver Assistance and ...
... SAN FRANCISCO, July 29 Medivation, Inc. (Nasdaq: ... and webcast with management to discuss second quarter 2009 financial results ... at 4:30 p.m. Eastern Time. A press release for the second ... on August 5, 2009. , , Interested parties ...
... , , , , ... Carefx Corporation , a leading provider of interoperable workflow ... that one of its clients, the Louisiana Rural Health Information Exchange (LARHIX), ... Health Information Executives , a top healthcare information technology magazine. ...
... , , MONROVIA, ... ), a leading developer, manufacturer and marketer of minimally invasive ophthalmic ... Officer will present at the BMO Capital Markets 9th Annual Focus ... 5th at 4:00 pm Eastern Time. , , ...
Cached Medicine News:Health News:Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August 2Health News:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009 2Health News:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009 3Health News:Wounded Warrior Project (WWP) Pushes for Senate Bill to Assist Family Caregivers of the Most Severely Injured Veterans 2Health News:Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009 2Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 2Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 3
... to U.S. and international engineering and ... Screw and Plating System* provides seamless ... of use for open reduction internal ... TC-100 system works well beyond the ...
... The Alphatec Small Fragment ... wide range of fractures, including ... distal humerus, distal radius, distal ... malleolus, metatarsals, and metacarpals. The ...
Stainless steel threaded Steinman Pins available in point types A,D, E, and F....
Round Bevel-Point Pin Sets available in 2.3mm, 3.1mm, 4.7mm, and 6.3mm sizes....
Medicine Products: